Coronavirus´impact on current product portfolio

Novo Nordisk Pharmatech A/S is continuously reviewing the likely impact upon its supply chain if product availability is affected by the consequences of the coronavirus. Presently, we conclude that the impact on current product portfolio is very limited. We will keep our customers informed of developments that might affect product supply and demand if the situation changes.

You can read the full statement here

Thursday 12.03.2020